Economic Costs of Chikungunya Virus in Colombia

Alvis-Zakzuk, Nelson J.; Díaz-Jiménez, Diana; Castillo-Rodríguez, Liliana; Castañeda-Orjuela, Carlos; Paternina-Caicedo, Ángel; Pinzón-Redondo, Hernando; Carrasquilla-Sotomayor, M; Alvis-Guzmán, Nelson; Hoz-Restrepo, Fernando De la

doi:10.1016/j.vhri.2018.01.004

Cited by 23 publications

(20 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is well known that CHIKV infection is self-limiting, resolving over time, and with a low mortality rate; however it causes considerable pain and disability, making it a public health issue mainly due to significant economic burden to the health system, families and society [86–89]. A recent study in Colombia estimated an economic cost per CHIKV patient of 152.9 USD, with an overall cost for the epidemic between 2014 and 2015 of 67 million USD [87]. For these reasons we evaluated the disability in our patients using three tools, HAQ-DI, EQ-5D, and EQ-5D VAS.…”

Section: Discussionmentioning

confidence: 99%

Chikungunya in Colombia: a description of an epidemic within the framework of a COPCORD study

Rueda

Santos

Angarita

et al. 2018

Preprint

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Chikungunya in Colombia: a description of an epidemic within the framework of a COPCORD study

Rueda

Santos

Angarita

et al. 2018

Preprint

View full text Add to dashboard Cite

show abstract

“…En cuanto a la enfermedad crónica, la prevalencia reportada varió entre las diferentes cohortes, desde un mínimo de 25 % en un grupo de 485 individuos y un periodo de seguimiento de 20 meses, hasta un máximo de 89 % en 39 individuos y un periodo de seguimiento de 37 semanas. Además de los signos reumatológicos, se reportó rigidez matutina, edema articular y enrojecimiento articular (104)(105)(106)(107)(108).…”

Section: Brote Epidémico Colombianounclassified

Reconociendo el virus del chikunguña

et al. 2021

View full text Add to dashboard Cite

El virus de chikunguña (CHIKV) es un Alfavirus perteneciente al grupo denominado del Viejo Mundo; estos son virus artritogénicos que causan una enfermedad febril caracterizada por artralgias y mialgias. Aunque la muerte por CHIKV es poco frecuente, la enfermedad puede llegar a ser incapacitante y generar un amplio espectro de manifestaciones atípicas, como complicaciones cardiovasculares, respiratorias, oculares, renales y dérmicas, entre otras. Cuando el dolor articular persiste por tres o más meses, da lugar a la forma crónica de la enfermedad denominada reumatismo inflamatorio crónico poschikunguña, el cual es la principal secuela de la enfermedad. Se considera que este virus no es neurotrópico, sin embargo, puede afectar el sistema nervioso central y generar secuelas graves y permanentes, principalmente, en niños y ancianos.En África, Asia y Europa se habían reportado anteriormente brotes epidémicos por CHIKV, pero solo hasta finales del 2013 se documentó la introducción del virus a las Américas; desde entonces, el virus se ha propagado a 45 países o territorios del continente y el número de casos acumulados ascendió a cerca de dos millones en dos años.Esta revisión describe de manera general la biología molecular del virus, sus manifestaciones clínicas, su patogénesis y las principales complicaciones posteriores a la infección. Además, reúne la información de la epidemia en Colombia y el continente americano publicada entre el 2014 y el 2020.

show abstract

“…Although alphavirus infections are generally not life threating the economic and social costs incurred during outbreaks are thought to be high [ 17 , 18 , 19 ]. Moreover, the lack of approved treatments leaves management of alphavirus infections to supportive care [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape

Torres‐Ruesta

Chee

2021

Microorganisms

View full text Add to dashboard Cite

Alphaviruses are mosquito-borne pathogens distributed worldwide in tropical and temperate areas causing a wide range of symptoms ranging from inflammatory arthritis-like manifestations to the induction of encephalitis in humans. Historically, large outbreaks in susceptible populations have been recorded followed by the development of protective long-lasting antibody responses suggesting a potential advantageous role for a vaccine. Although the current understanding of alphavirus antibody-mediated immunity has been mainly gathered in natural and experimental settings of chikungunya virus (CHIKV) infection, little is known about the humoral responses triggered by other emerging alphaviruses. This knowledge is needed to improve serology-based diagnostic tests and the development of highly effective cross-protective vaccines. Here, we review the role of antibody-mediated immunity upon arthritogenic and neurotropic alphavirus infections, and the current research efforts for the development of vaccines as a tool to control future alphavirus outbreaks.

show abstract

Economic Costs of Chikungunya Virus in Colombia

Cited by 23 publications

References 19 publications

Chikungunya in Colombia: a description of an epidemic within the framework of a COPCORD study

Chikungunya in Colombia: a description of an epidemic within the framework of a COPCORD study

Reconociendo el virus del chikunguña

Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape

Contact Info

Product

Resources

About